Evidence map›Paper›PMID 39413182›Full record

ArticleScience advances2024

Hypertrophic cardiomyopathy-associated mutations drive stromal activation via EGFR-mediated paracrine signaling.

Jourdan K Ewoldt, Miranda C Wang, Micheal A McLellan, Paige E Cloonan, Anant Chopra, Joshua Gorham, Linqing Li, Daniel M DeLaughter, Xining Gao, Joshua H Lee and 8 more

Abstract read
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Cardiac disease mechanobiology: advances using hiPSC-CMs.Frontiers in cardiovascular medicine · 2025
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jourdan K EwoldtDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.ORCID 0000-0001-5466-8557
Miranda C WangDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.ORCID 0000-0002-9534-5276
Micheal A McLellanDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.ORCID 0000-0003-1946-5038
Paige E CloonanDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
Anant ChopraDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
Joshua GorhamDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-5969-4690
Linqing LiDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.ORCID 0000-0003-3003-9902
Daniel M DeLaughterDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5352-2502
Xining GaoDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
Joshua H LeeDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.ORCID 0009-0004-7699-4555
Jon A L WillcoxDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-3782-4770
Olivia LaytonDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA.
Rebeccah J LuuDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.ORCID 0000-0003-4364-8985
Christopher N ToepferDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-4671-2030
Jeroen EyckmansDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.ORCID 0000-0003-1475-8149
Christine E SeidmanDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-6380-1209
Jonathan G SeidmanDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-9082-3566
Christopher S ChenDepartment of Biomedical Engineering, Boston University, Boston, MA 02215, USA.ORCID 0000-0003-2445-8449

Funding

Molecular Signaling in Hypertrophic CardiomyopathyR01HL084553 · NHLBI · HARVARD MEDICAL SCHOOL · PI SEIDMAN, JONATHAN G · 2007 to 2022
$5.9M
Hypertrophic cardiomyopathy-induced paracrine signaling and stromal activationF31HL158195 · NHLBI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI EWOLDT, JOURDAN · 2021 to 2023
$101k
NHLBI NIH HHS F31 HL158195NHLBI NIH HHS R01 HL084553Wellcome Trust
6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM) is characterized by thickening of the left ventricular wall, diastolic dysfunction, and fibrosis, and is associated with mutations in genes encoding sarcomere proteins. While in vitro studies have used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to study HCM, these models have not examined the multicellular interactions involved in fibrosis. Using engineered cardiac microtissues (CMTs) composed of HCM-causing

Indexed as

Cardiomyopathy, HypertrophicErbB ReceptorsInduced Pluripotent Stem CellsMutationMyocytes, CardiacParacrine CommunicationCardiac MyosinsCarrier ProteinsCell ProliferationFibroblastsFibrosisHumansMyosin Binding Protein CMyosin Heavy ChainsStromal CellsCardiac MyosinsCarrier ProteinsEGFR protein, humanErbB ReceptorsMYH7 protein, humanMyosin Binding Protein CMyosin Heavy Chains

Identifiers

PMID39413182
PMCPMC11482324

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.